Vertex Reports Second Quarter 2026 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vertex Pharma (VRTX) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY26 Revenue Guidance
August 3, 2026 4:02 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $4.73, $0.01 better than the analyst estimate of $4.72. Revenue for the quarter came in at $3.33 billion versus the consensus estimate of $3.22 billion.
GUIDANCE:
Vertex Pharma sees FY2026 revenue of $13.1-13.2 billion, versus the consensus of... More
